The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | Better survival outcomes with the use of new CLL drugs
Claire Dearden, MBBS, MD, FRCP, FRCPath from the Royal Marsden Hospital, London, UK discusses the use of new drugs in the treatment of chronic lymphocytic leukemia (CLL) and the importance of a collaborative team effort to produce telling data. First-line treatment of ibrutinib and idelalisib is successful for over 50% of patients; however, the majority still require further treatment, and there are ongoing clinical trials for new drugs to be used as a second-line treatment, like venetoclax. The CLL forum data is a collaborative effort of UK hematologists and it has indicated that venetoclax can increase survival outcome of patients that relapse in the second year of treatment. This interview was recorded at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
